Six different studies will report on use of ImmuKnow assay in presentations at the annual meeting of the International Society for Heart and Lung
COLUMBIA, Md., April 9 /PRNewswire/ -- Since it was initially cleared as an in vitro diagnostic technique to detect cell-mediated immunity (CMI) in immune-suppressed adult patients, understanding of the possible applications of the Cylex(TM) ImmuKnow(R) assay (in clinical practice and in the clinical research setting) has been continuously expanding.
On Wednesday, April 9 through Saturday, April 12, at the annual meeting
of the International Society for Heart and Lung Transplantation (ISHLT)
Meeting in Boston, MA, an additional six presentations will report on
studies of the use of the ImmuKnow assay in a variety of heart and lung
Thursday, April 10
-- "Use of an immune monitoring assay to distinguish between fungal
colonization and fungal disease in lung transplant recipients"
(S. Husain, J. Pilewski, K. Spichty, et al.) -- oral presentation,
4:15 p.m. - 5:45 p.m. (Oral Session: Management of Emerging Infection
in Heart and Lung Transplantation)
-- "Immune cell function testing for the optimization of the therapeutic
drug monitoring in selected heart transplant patients, a case series"
(T. Ben Gal, V. Yaari, M. Israeli, et al.) -- poster presentation,
5:45 p.m. - 6:45 p.m. (General Posters: Poster Session II)
Friday, April 11
-- "Success of immune monitoring with ImmuKnow (Cylex) to assess
rejection/infectious risk in heart transplantation" (J. A. Kobashigawa,
K. K. Kiyosaki, J. K. Patel, et al.) - oral presentation, 10:45 a.m. --
12:45 p.m. (Oral Session: Can We Predict, Diagnose and Treat Cardiac
Rejection and Vasculopathy Before It's Too Late?)
-- "Assessment of the Cylex ImmuKnow cell fu
|SOURCE Cylex Inc.|
Copyright©2008 PR Newswire.
All rights reserved